Ziprasidone

Excerpt

Ziprasidone, an atypical antipsychotic, is approved by the US Food and Drug Administration (FDA) for the treatment of schizophrenia, bipolar mania, and acute agitation in individuals with schizophrenia. In schizophrenia treatment, the drug exerts therapeutic antagonism on dopamine (D2) and serotonin (5HT2) receptors. However, due to its antagonism with H1 receptors, ziprasidone may induce somnolence. Studies have demonstrated that ziprasidone was markedly superior to placebo in both the rate and duration of relapse when treating schizophrenia. The research confirmed the efficacy of ziprasidone in bipolar disorder, also highlighting improvement on the manic syndrome subscale. This scale assesses symptoms of mania, including mood, insomnia, excessive energy and activity, as well as overall behavior and ideation.